Immunodeficiency References

pdfASCIA HP Immunodeficiency References 2020182.85 KB  

Abolhassani, H., Sadaghiani, M. S., Aghamohammadi, A., Ochs, H. D., & Rezaei, N., (2012). Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: Systematic review and meta-analysis. J Clin Immunol, 32(6), 1180-1192.

Åhlin, A., Fugeläng, J., de Boer, M., Ringden, O., Fasth, A., & Winiarski, J. (2013). Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr, 102(11), 1087-9

Al-Herz, W., Bousfiha, A., Casanova, J. L., Chatila, T., Conley, M. E., Cunningham-Rundles, C., … Tang, M. L. (2014). Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Frontiers in Immunology, 22(5), 162.

Ameratunga, R., Woon, S. T., Brewerton, M., Koopmans, W., Jordan, A., Brothers, S., & Singh, R. (2011). Primary immune deficiency disorders in the South Pacific: the clinical utility of a customized genetic testing program in New Zealand. Ann N Y Acad Sci, 1238(1), 53-64.

Ameratunga, R., Woon, S. T., Gillis, D., Koopmans, W., & Steele, R. (2013). New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol, 174(2), 203-11.

ASCIA-TAPID Consensus Guideline: Diagnosis, management and transplantation of severe combined immunodeficiency in Australia and New Zealand. 2019

Asia Pacific Immunoglobulins in Immunology Expert Group (APIIEG) (2009) Consensus Recommendations for the use of Immunoglobulin Replacement Therapy in Immune Deficiency.

Berger, M., (2011). Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol, 31 (5), 924-926.

Bezrodnik, L. Raccio, A., G., Belardinelli, G., Regairaz, L., Ballve, D. D., Seminario, G., … Giovanni, D. D. (2013). Comparative study of subcutaneous versus intravenous IgG replacement therapy in paediatric patients with primary immunodeficiency diseases: A multicentre study in Argentina. J Clin Immunol, 33, 1216-1222.

Bonilla, F. A., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Hsu, J. T., … Wallace D. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. (2015). Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol, 136(5).

Chapel, H., Prevot, J., Gaspar, H.B., Espanol, T., Bonilla, F.A., Solis, L., Drabwell, J. & The Editorial Board for Working Party on Principles of Care at IPOPI. (2014). Primary immune deficiencies – principles of care. Front Immunol, (5), 627.

Cole, T., McLean‐Tooke, A., Loh, R., Quinn, P., Peake, J., Sinclair, J., & Smart, J. (2018). ASCIA transplantation and primary    immunodeficiency (TAPID) project. Internal Medicine Journal, 48, Issue S6.

Cole, T., Pearce, M. S., Cant, A. J., Cale, C. M., Goldblatt, D., & Gennery, A. R. (2013). Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 132(5), 1150-5.  10.1016/j.jaci.2013.05.031

EBMT/ESID Guidelines for haematopoietic stem cell transplantation (HSCT) for primary                                         immunodeficiencies HSCT Guidelines. (2017).

Gardulf, A. (2007). Immunoglobulin treatment for primary antibody deficiencies: Advantages of the subcutaneous route. Biodrugs.

Gaspar, J., Gerritsen, B., & Jones, A., (1998). Immunoglobulin replacement treatment by rapid subcutaneous infusion. Archives of Disease in Childhood, 79 (1), 48-51.

Gray, P. E., Namasivayam, M., & Ziegler, J. B. (2012). Recurrent infection in children: when and how to investigate for primary immunodeficiency? J Paediatr Child Health, 48(3), 202-209.

Jolles, S.  & Sleasman, J. W., Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach. (2011). Adv Ther, 28(7), 521-533.

Kang, E. M., Marciano, B. E., DeRavin, S., Zarember, K. A., Holland, S. M., & Malech, H. L., (2011). Chronic Granulomatous disease: Overview and hematopoietic stem cell transplantation. J Clin Immunol Allergy, 127(6), 1319-1326.

Kirkpatrick, P. & Riminton, S. (2007). Primary immunodeficiency diseases in Australia and New Zealand, J Clin Immunol, 27(5), 517-24.

Kobrynski, L. (2012). Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics:Targets and Therapy, 6, 277-287.

Lingman-Framme, J., & Fasth, A. (2013). Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs, 73, 1307-1319.

Mitchell, R., Nivison-Smith, I., Anazodo, A., Tiedemann, K., Shaw, P., Teague, L. … O’Brien, T.A. (2013). Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children’s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Biology of Blood and Marrow Transplantation, 19(3), 338-343.

Neven, B. & Furrua, F., (2020).  Hematopoietic Stem Cell Transplantation for Combined Immunodeficiencies, on behalf of IEWP-EBMT. Front Pediatr

Nicolay, U., Haag, S., Eichmann, F., Herget, S., Spruck, D., & Gardulf, A. (2005). Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Quality of Life Research, 14(7), 1683-1691.

Ochs, H.D., Gupta, S., Kiessling, P., Nicolay, U., Berger, M. & Subcutaneous IgG Study Group. (2006) Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol Allergy, 26 (3), 265-273.

Picard, C., Gaspar, H. B., Al-Herz, W., Bousfiha, A., Casanova, J., Chatila, T., … Sullivan, K. E. (2017). International Union of Immunological Societies Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol, 38, 96-128.

Radinsky S, Bonagura VR. (2003). Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol, 112, 630-633.

Richards, S., Gennery, A.R., Davies, G., Wong, M., Shaw, P.J., Peake, J., … Cole, T., on behalf of ASCIA Transplantation and Primary Immunodeficiency (TAPID) group. (2020). Diagnosis and management of severe combined immunodeficiency in Australia and New Zealand. Journal of Paediatrics and Child Health, 56, 1508–1513.

Riminton, D. S., Hartung, H. P., & Reddel, S. W. (2011). Managing the risks of immunosuppression. Curr Opin Neurol, 24(3), 217-23.

Seger, R. A. (2010). Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease, Immunol allergy Clin N Am, 30, 195-208.

Slade, C. A., Bosco, J., Giang, T. B., Kruse, E., Stirling, R.G., Cameron, P. U., … van Zelm, M. C. (2018). Delayed Diagnosis and Complications of Predominantly Antibody Deficiencies in a Cohort of Australian Adults. Front Immunol,

Soncini, E., Slatter, M. A., Jones, L. B., Hughes, S., Hodges, S., Flood, T. J., … Gennery, A. R. (2009). Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 145(1),73-83.

Stiehm, E.R., Casillas, A.M., Finkelstein, J.Z., Gallagher, K.T., Groncy, P.M., Kobayashi, R.H., … Wakim, M. E. (1998). Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clinical Immunol, 101 (6 Pt 1), 848-9.

Tangye, S., Al-Herz, W., Bousfiha, A., Chatila, T., Cunningham-Rundles, C., Etzoni, A., … Sullivan, K. (2020). Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol, 40, 24-64.  

Uzel, G., Orange, J. S., Poliak, N., Marciano, B. E., Heller, T., & Holland, S., M. (2010). Complications of Tumor Necrosis Factor-± Blockade in Chronic Granulomatous Disease—Related Colitis. Clin Infect Dis, 51(12), 1429–1434.

Younger, M. E. M (ed), IDF (Fourth Edition, 2016) Guide for Nurses. Immunoglobulin Therapy for Primary Immunodeficiency Diseases. Immune Deficiency Foundation.

Younger, M. E., Aro, L., Blouin, W., Duff, C., Epland, K. B., Murphy, E., & Sedlak, D. (2013). Nurse Advisory Committee Immune Deficiency Foundation. Nursing guidelines for administration of immunoglobulin replacement therapy. J Infus Nurs. 36(1), 58-68.

NOTE: There is a separate ASCIA reference list for Hereditary Angioedema (HAE) publications on the ASCIA website

Content updated October 2020 

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia